Salvia announces first MySalvia implant in U.S. pivotal migraine trial
Source publication date
Site published
The procedure took place at Vista Clinical Research in Newnan, Georgia. The randomized, double-blind controlled study plans roughly 150 adults at over 20 U.S. sites.
Two thin implants beneath the front and back scalp deliver electrical stimulation to migraine-related nerves, activated by an external wearable. This is nerve modulation, not muscle-stimulating EMS.
Summary
The October 15 announcement marks the first U.S. RECLAIM-II implantation of investigational MySalvia.
Editorial view
Editorial view: a development milestone from early studies to a larger controlled U.S. trial. Recruitment, safety and comparative outcomes remain key evidence to follow.
Evidence and limitations
Investigational and not commercially authorized. First implantation does not establish efficacy or commercial availability. October 15 is the announcement date; the exact procedure date was not disclosed.